Fundraising Fox

Elastrin Therapeutics

Greenville, US · Founded 2017 · Delaware corporation

Biotech

Founders & leadership

Elastrin Therapeutics was founded in 2017 by Naren Vyavahare.

NV
Naren VyavahareFounder
MB
Matthias BreugelmansNamed on SEC filing

Board

PB
Patrick BurgermeisterBoard director

Reported raises · per SEC filings

Form D private placements

$13.3M disclosed across 5 rounds · 2021–2024

▶$500KraisedMar 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Naren VyavahareExecutive Officer, Director
Offering amount
$500K
Amount sold
$500K
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick BurgermeisterDirector
  • Klaus-Dieter LangnerDirector
  • Naren VyavahareExecutive Officer, Director
  • Matthias BreugelmansExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthias BreugelmansExecutive Officer, Director
  • Naren VyavahareExecutive Officer, Director
  • Klaus-Dieter LangnerDirector
  • Patrick BurgermeisterDirector
Offering amount
$4.8M
Amount sold
$4.8M
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick BurgermeisterDirector
  • Naren VyavahareExecutive Officer, Director
  • Matthias BreugelmansExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$2.5M
Finders' fees
$180.8K
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6MraisedMar 2022 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthias BreugelmansExecutive Officer, Director
  • Naren VyavahareExecutive Officer, Director
  • Patrick BurgermeisterDirector
Offering amount
$10M
Amount sold
$3.6M
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2019$284K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Elastrin Therapeutics | Lifespan Research Institutelifespan.io · Jul 2025SC Launch, Inc. Announces Investment in Elastrin Therapeutics - SCRA: South Carolina Research Authorityscra.org · May 2022Elastrin Therapeutics Closes $10M Funding Roundfinsmes.com · Apr 2022Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Roundelastrin.com · Apr 2022Biotech Startup Elastrin Therapeutics Receives Seed Funding From KIZOO - Life Sciences, Biotechnology & Nanotechnology - Canadamondaq.com · Mar 2021Elastrin limbers up for success with Kizoo funding boostlongevity.technology · Mar 2021

Frequently asked questions

Who founded Elastrin Therapeutics?
Elastrin Therapeutics was founded by Naren Vyavahare in 2017.
How much funding has Elastrin Therapeutics raised?
Elastrin Therapeutics has disclosed $13.3M raised across 5 rounds.
Where is Elastrin Therapeutics headquartered?
Elastrin Therapeutics is headquartered in Greenville, US.